

# NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

## Company

2024/08/16 17:31:02



Price

**7.60** CHF

Difference ▲ 5.26% (0.38)



## Contact Details

NEWRON PHARMACEUTICALS  
SPA

Tel: +39-02-610-3461

--

Fax: +39-02-610-34654

via Antonio Meucci 3

Web:

<https://www.newron.com/>

20091 Bresso

E-mail: [info@newron.com](mailto:info@newron.com)

## Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	18,271,000		28,134,000		40,852,000	
<b>Common stock capital</b>		3,318,000		3,524,000		3,698,000
<b>Fixed assets</b>	5,777,000		8,592,000		11,458,000	
<b>Equity capital of a company</b>		-27,806,000		-13,853,000		3,219,000
<b>Cash and cash equivalents</b>	5,892,000		13,255,000		25,923,000	
<b>Accrued liabilities</b>		383,000		468,000		602,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		26,893,000		4,977,000		3,786,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		24,961,000		45,602,000		45,306,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		439,000		217,000		220,000
<b>Total assets</b>	24,048,000	24,048,000	36,727,000	36,727,000	52,311,000	52,311,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	-	-	-
<b>Equity ratio</b>	-115.63%	-37.72%	6.15%
<b>Debt-equity ratio</b>	-186.49%	-365.11%	1,524.91%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-0.15%	-0.12%	-0.11%

# NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	8,799,000	6,116,000	6,226,000
<b>Net income</b>	-15,762,000	-17,558,000	-16,102,000
<b>EBIT</b>	-11,906,560	-13,989,840	-13,697,239
<b>Operating income before taxes</b>	-15,739,000	-17,537,000	-16,084,000
<b>Cash Flow</b>	-9,851,000	-11,133,000	-12,367,000
<b>Net interest income</b>	-4,478,000	-4,307,000	-3,130,000
<b>Research and development expenses</b>	12,710,000	11,981,000	11,522,000
<b>Income taxes</b>	23,000	21,000	18,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	-	-	-

## Board of Directors

Ulrich Köstlin	Chairman of Supervisory Board
Luca Benatti	Member of Supervisory Board
Patrick Langlois	Member of Supervisory Board
Gillian Dines	Member of Supervisory Board
Margarita Chavez	Member of Supervisory Board

## Members of Management Board

Stefan Weber	Chairman of Managing Board
Dennis Dionne	Member of Executive Committee
Filippo Moriggia	Member of Executive Committee
Laura Faravelli	Member of Executive Committee
Ravi Anand	Member of Executive Committee
Roberto Galli	Member of Executive Committee